10-K: Syra Health Corp. Reports Increased Revenue but Continues to Face Going Concern Doubts in Annual 10-K Filing

Sentiment:

Annual Results 11 March 2025 5:00 PM

Syra Health Corp.'s annual report reveals revenue growth alongside ongoing concerns about its ability to continue as a going concern without additional financing.

Capital raiseThe company states it may need to seek additional funds sooner than planned, through public or private equity or debt financings or other third-party funding or a combination of these approaches.The company's ability to continue as a going concern is dependent on obtaining additional equity or debt financing, reducing expenditures, and generating significant revenue.

Worse than expectedThe company's net losses increased, and its gross profit margin decreased.The independent auditor expressed substantial doubt about the company's ability to continue as a going concern.

Summary

Syra Health Corp. reported revenues of $8.0 million for the year ended December 31, 2024, compared to $5.5 million in 2023.
The company's net losses were $3.8 million and $2.9 million for 2024 and 2023, respectively, with an accumulated deficit of $8.8 million as of December 31, 2024.
Syra's independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.
The company's ability to continue as a going concern is dependent on obtaining additional equity or debt financing, reducing expenditures, and generating significant revenue.
Syra launched its Syrenity mental health application in the third quarter of 2024.
The company employed 57 full-time and 37 part-time employees as of March 7, 2025.
FSSA accounted for approximately 61% and 68% of the company's revenues for the years ended December 31, 2024 and 2023, respectively.

Sentiment

Score: 4

Explanation: While revenue increased, the increasing net losses and going concern warning from the auditor significantly dampen the sentiment. The company faces considerable financial challenges.

Positives

The company experienced a significant increase in net revenue, driven by growth in healthcare workforce and population health services.
Syra launched Syrenity, a comprehensive mental health application, in the third quarter of 2024.
The company is expanding its services and targeting growth in the digital health market.

Negatives

The company's net losses increased, and its gross profit margin decreased.
The independent auditor expressed substantial doubt about the company's ability to continue as a going concern.
The company is heavily reliant on a small number of large customers, particularly FSSA.

Risks

The company faces significant competition in the healthcare services market.
Syra's business strategy depends on its ability to cross-sell its solutions.
The company's work with government clients exposes it to additional risks inherent in the government contracting environment.
The dual-class structure of the company's common stock concentrates voting control with certain stockholders.
The company may be liable for misdiagnoses or mistreatment resulting from the use of data it provides to healthcare providers.

Future Outlook

The company expects that its existing cash and cash from revenue will be sufficient to fund its current operations through at least 12 months from the date of the annual report, but may need to seek additional funds sooner than planned.

Industry Context

The report mentions market opportunities and growth rates for various segments, including behavioral and mental health, population health, digital health, health education, and healthcare workforce, indicating the company's alignment with broader industry trends.

Related Party Transactions

The company leases its corporate headquarters from STVentures, LLC, an entity beneficially owned by the principal owners and the management team of Syra and their affiliates.
The company incurred expenses for IT services from RAD CUBE LLC, an entity beneficially owned by the principal owners and the management team of Syra and their affiliates.
The company paid for recruitment and human resource services from NLogix, an entity beneficially owned by the principal owners and the management team of Syra and their affiliates.
Sahasra Technologies Corp., an entity beneficially owned by the principal owners and management team of Syra, made short term, non-interest bearing advances to the company.

Stakeholder Impact

Shareholders face the risk of dilution from potential future equity offerings.
Employees' job security is uncertain due to the company's going concern status.
Customers may be concerned about the company's ability to provide ongoing services due to its financial challenges.
Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

The company plans to open offices in multiple geographical locations to support sales and business development efforts.
Syra intends to invest in partnerships with subject matter experts to further enhance its service lines.
The company may expand its footprint by acquiring companies that offer similar service lines.
Syra is strategically preparing for the launch of Syrenity in global markets.

Key Dates

Date	Description
2020-11-20	Syra Health Corp. was organized as an Indiana corporation.
2021-07-01	Commencement date of the three-year lease for the corporate headquarters.
2022-02-07	Date of the business loan agreement with Citizens State Bank of New Castle.
2022-03-11	Syra Health Corp. converted from an Indiana corporation to a Delaware corporation.
2022-04-11	Date of adoption of the Syra Health Corp. 2022 Omnibus Equity Incentive Plan.
2022-05-01	Amendment to the corporate headquarters lease agreement.
2023-01-01	Start of the period for convertible promissory notes and subscription agreements.
2023-04-07	Date of subscription agreements for convertible promissory notes.
2023-07-11	Start date of short term, non-interest bearing advances from Sahasra Technologies Corp.
2023-08-23	End date of short term, non-interest bearing advances from Sahasra Technologies Corp.
2023-10-03	Completion date of Syra Health Corp.'s initial public offering (IPO).
2024-01-01	Start of the period for Employee Retention Tax Credit.
2024-06-26	Further amendment to the corporate headquarters lease agreement.
2024-07-01	Commencement date of the additional three-year term of the corporate headquarters lease.
2024-08-13	Date of notification from Nasdaq regarding stockholders equity below minimum requirement.
2024-09-11	Completion date of the public offering of Class A common stock and warrants.
2024-10-18	Date of notification from Nasdaq regarding bid price below minimum requirement.
2025-01-17	Conversion of Class B Common Stock to Class A Common Stock by Executive Chairman and President.
2025-03-07	Date as of which the number of shares of Class A Common Stock outstanding was reported.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.